November 8, 2014
Notes: Kaur, Ravneet Ruby
Glick, Jaimie B
Indian Dermatol Online J. 2013 Apr;4(2):71-81. doi: 10.4103/2229-5178.110575.
Author Address: Department of Dermatology, SUNY Downstate Medical Center, 450 Clarkson Avenue Brooklyn, NY 11203, USA.
Reference Type: Journal Article
Record Number: 4329Author: Kestenbaum, T.
Title: Obsessive-compulsive disorder in dermatology
Journal: Semin Cutan Med Surg
Short Title: Obsessive-compulsive disorder in dermatology
Alternate Journal: Seminars in cutaneous medicine and surgery
ISSN: 1085-5629 (Print)
Accession Number: 24049965
Abstract: Obsessive-compulsive disorder (OCD) is a very common disorder affecting 2% to 3% of the general population. Up to 25% of patients presenting to physicians with skin disease suffer from OCD. Only 20% of all patients with OCD are receiving treatment. Unfortunately, those few receiving treatment remained undiagnosed for many years. Standard treatment includes behavioral therapy and psychotropic drugs (ie, selective serotonin re-uptake inhibitors and clomipramine). The highest dosages of these medications must be used for at least 3 months to see proper effectiveness and maintained for lengthy periods of time. Not only are there abnormalities in the serotonin pathway of patients with OCD but also the glutamate pathway is abnormal, leading to possible new treatment strategies.
Notes: Kestenbaum, Thelda
Semin Cutan Med Surg. 2013 Jun;32(2):83-7.
Author Address: Division of Dermatology, Mail Stop 2025, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160, USA. email@example.com